Denali Therapeutics (DNLI) Shares Issued (2017 - 2018)

Denali Therapeutics (DNLI) posted quarterly Shares Issued of $1.5 million for Q1 2018, down 78.05% quarter-over-quarter from $6.7 million in Q4 2017.

Denali Therapeutics (DNLI) Shares Issued (2017 - 2018) Analysis & Trends

Denali Therapeutics (DNLI) has reported Shares Issued for 2 consecutive years, with $1.5 million the latest figure, recorded in Q1 2018.

In Q1 2018, Shares Issued changed N/A year-over-year to $1.5 million; the TTM figure through Mar 2018 stood at $1.5 million (changed N/A YoY), while the FY2017 annual figure was $6.7 million, changed N/A from the prior year.
Shares Issued declined to $1.5 million in Q1 2018 per DNLI's latest filing, from $6.7 million in the prior quarter.
Across five years, Shares Issued topped out at $6.7 million in Q4 2017 and bottomed at $1.5 million in Q1 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Shares Issued (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	-
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	18.36 Mn
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	-
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-
10	Denali Therapeutics	3.90 Bn	3.90 Bn	3.51 Mn	-

Download Data